Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  American Journal of Kidney Diseases

• Publication date

  2015-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.ajkd.2015.06.013PMID 26209543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IgA nephropathy.

  2020cited by this paper
• Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

  2014cited by this paper
• Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy

  2013cited by this paper
• The Oxford classification as a predictor of prognosis in patients with IgA nephropathy.

  2012cited by this paper
• Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification).

  2012cited by this paper
• Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil

  2012cited by this paper
• Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression.

  2012cited by this paper
• Current therapy for IgA nephropathy.

  2011cited by this paper
• Validating the oxford classification of IgA nephropathy.

  2011cited by this paper
• Validation of the Oxford classification of IgA nephropathy.

  2011cited by this paper
• Long-term study of mycophenolate mofetil treatment in IgA nephropathy.

  2010cited by this paper
• The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.

  2010cited by this paper
• The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.

  2009cited by this paper
• Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review.

  2008cited by this paper
• Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-Analysis

  2008cited by this paper
• IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.

  2007cited by this paper
• Remission of proteinuria improves prognosis in IgA nephropathy.

  2007cited by this paper
• Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.

  2005cited by this paper
• Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy.

  2005cited by this paper
• A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine

  2004cited by this paper
• A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]

  2004cited by this paper
• Carolinas Medical Center

  2004cited by this paper
• Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.

  2004cited by this paper
• Effect of losartan and amlodipine on proteinuria and transforming growth factor‐β1 in patients with IgA nephropathy

  2003cited by this paper
• Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.

  2003cited by this paper
• Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.

  2003cited by this paper
• [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy].

  2002cited by this paper
• Evidence-based assessment of treatment options for children with IgA nephropathies

  2001cited by this paper
• Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis.

  1998cited by this paper
• Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.

  1994cited by this paper
• A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.

  1994cited by this paper
• In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443.

  1991cited by this paper
• Bone marrow dysfunction in irradiated, cytomegalovirus-infected mice.

  1991cited by this paper
• The commonest glomerulonephritis in the world: IgA nephropathy.

  1987cited by this paper
• [IgA nephropathy].

  1985influential reference
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• A Coefficient of Agreement for Nominal Scales

  1960cited by this paper

• Treatment of Patients with IgA Nephropathy: A call for a new paradigm.

  2025cites this paper
• Comparative Efficacy and Safety of Pharmacological Interventions for IgA Nephropathy: A Systematic Review and Meta-Analysis

  2025cites this paper
• Concomitant IgA nephropathy and dermatomyositis: a case-based review

  2025cites this paper
• Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation

  2025cites this paper
• Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study

  2025cites this paper
• Iptacopan in Patients With IgA Nephropathy From East Asia

  2025cites this paper
• KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

  2025cites this paper
• Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety

  2025cites this paper
• Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy

  2025cites this paper
• Intraglomerular Inflammation as a Guide for Mycophenolate Mofetil-Based Treatment in IgA Nephropathy

  2025influential citation
• IgA nephropathy: a paradigm shift in treatment strategies.

  2025cites this paper
• Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials

  2025cites this paper
• Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis

  2025cites this paper
• Applying Exposure-Response analysis to Enhance Mycophenolate Mofetil Dosing Precision in Pediatric Patients with Immune-mediated Renal Diseases by Machine Learning Models.

  2025cites this paper
• An Expert Opinion on Current and Future Treatment Approaches in IgA Nephropathy

  2025cites this paper
• Kidney Outcomes with Corticosteroid Treatment in IgA Nephropathy According to the Oxford-MEST-C Classification

  2025cites this paper
• Treatment of immunoglobulin A nephropathy: Current perspective and future prospects

  2025cites this paper
• The Rapidly Changing Treatment Landscape of IgA Nephropathy.

  2025cites this paper
• Retrospective Analysis of the Outcomes of Mycophenolate Therapy in Retarding the Progression of Immunoglobulin A Nephropathy (REMISSION IgA)

  2025cites this paper
• From genomic insights to clinical hope: Targeting NEU1 in IgA nephropathy.

  2024cites this paper
• Emerging perspectives in the management of IgA nephropathy: a comprehensive review

  2024cites this paper
• IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis

  2024cites this paper
• Off-Label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis

  2024cites this paper
• Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials

  2024cites this paper
• Treatment of Patients with IgA Nephropathy: Evaluation of the Safety and Efficacy of Mycophenolate Mofetil.

  2024cites this paper
• Immunosuppressive therapy for IgA nephropathy in children.

  2024cites this paper
• Optimizing Immunosuppression in Glomerular Diseases

  2024cites this paper
• New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023?

  2024cites this paper
• An Update on Current Therapeutic Options in IgA Nephropathy

  2024cites this paper
• Hydroxychloroquine Induces Remission for IgA Nephropathy With Mild to Moderate Proteinuria: A Single-Centered Retrospective Analysis

  2024cites this paper
• Mycophenolate mofetil plus steroids compared to steroids alone in IgA nephropathy: a retrospective study

  2023cites this paper
• The Beneficial Effect of Three-month Induction Therapy with High-dose Prednisone and Mycophenolate Mofetil Followed by Maintenance Therapy in Acute Non-crescentic Nephritis Associated with Immunoglobulin A Deposition Disease in Adults.

  2023cites this paper
• Efficacy and safety of losartan in childhood immunoglobulin A nephropathy: a prospective multicenter study

  2023cites this paper
• Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis

  2023cites this paper
• Novel Treatment Paradigms: Primary IgA Nephropathy

  2023cites this paper
• Clinical Practice Patterns in IgA Nephropathy: A Global Questionnaire-Based Survey

  2023cites this paper
• The Treatment of Primary IgA Nephropathy: Change, Change, Change.

  2023cites this paper
• IgA nephropathy in adults—treatment standard

  2023cites this paper
• The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy

  2023influential citation
• A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy

  2022cites this paper
• IgA nephropathy: an overview of drug treatments in clinical trials

  2022cites this paper
• A clinical study of mycophenolate mofetil combined with low-dose steroids in the management of pediatric systemic lupus erythematosus

  2022cites this paper
• Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment

  2022influential citation
• Immunosuppressive therapy for IgA nephropathy in children

  2022cites this paper
• Management of IgA Nephropathy in Pediatric Patients

  2022cites this paper
• Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study.

  2021cites this paper
• Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis

  2021cites this paper
• Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: a meta-analysis of randomized controlled trials

  2021cites this paper
• IgA Vasculitis and IgA Nephropathy: Same Disease?

  2021cites this paper
• Is IgA nephropathy the same disease in different parts of the world?

  2021cites this paper
• Immunoglobulin A Nephropathy in Children

  2021cites this paper
• Overview of Traditional Chinese and Western Medicine Treatment of IgA Nephropathy

  2021cites this paper
• A Randomized, Controlled Trial of Prednisone Plus Cyclophosphamide in Patients with Advanced-stage IgA Nephropathy

  2021cites this paper
• Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function

  2021cites this paper
• KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

  2021cites this paper
• A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges

  2020cites this paper
• Efficacy and safety of Abelmoschus manihot for IgA nephropathy: A multicenter randomized clinical trial.

  2020cites this paper
• The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis

  2020influential citation
• Initial serum creatinine concentration affects clinical outcomes in patients with IgA nephropathy treated with mycophenolate mofetil combined with low-dose prednisone.

  2020cites this paper
• Immunosuppressive agents for treating IgA nephropathy.

  2020cites this paper
• Efficacy and safety of immunosuppressive agent monotherapy for IgA nephropathy: a network meta-analysis

  2020cites this paper
• Treatment of IgA nephropathy in children: a land without KDIGO guidance

  2020cites this paper
• IgA nephropathy in children and in adults: two separate entities or the same disease?

  2020cites this paper
• IgA-Nephropathie : Pathogenese , Klinik und Therapie VNR : 2760602020169570006

  2020cites this paper
• Emerging Modes of Treatment of IgA Nephropathy

  2020cites this paper
• IgA nephropathy: un update.

  2019cites this paper
• Is immunoglobulin A nephropathy different in different ethnic populations?

  2019cites this paper
• Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology

  2019cites this paper
• Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis

  2019cites this paper
• Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

  2019cites this paper
• Old and New Treatment Options in IgA Nephropathy and Henoch Schönlein Purpura Nephritis/IgA Vasculitis in Children

  2019cites this paper
• Improving Global Outcomes ( KDIGO ) Controversies Management and treatment of glomerular diseases ( part 1 ) : conclusions from a Kidney Disease : Conference

  2019cites this paper
• Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?

  2019cites this paper
• Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials

  2019cites this paper
• Treatment of IgA Nephropathy: Evolution Over Half a Century.

  2018cites this paper
• Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT

  2018cites this paper
• Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials

  2018cites this paper
• Pathophysiologie und Therapie der IgA-Nephropathie

  2018cites this paper
• Primary IgA nephropathy: current challenges and future prospects

  2018cites this paper
• Glomérulonéphrite primitive à dépôts mésangiaux d’immunoglobulines A

  2018cites this paper
• Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials

  2018cites this paper
• The Emerging Role of Pathogenesis of IgA Nephropathy

  2018cites this paper
• Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis

  2017cites this paper
• IgA Nephropathy.

  2017cites this paper
• A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

  2017cites this paper
• An update on the treatment of IgA nephropathy

  2017cites this paper
• Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment.

  2017cites this paper
• Immunosuppression in IgA Nephropathy: Guideline Medicine Versus Personalized Medicine.

  2017cites this paper
• Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.

  2017cites this paper
• Is there a role for immunosuppression in immunoglobulin A nephropathy?

  2017cites this paper
• Inflammation in IgA nephropathy

  2017cites this paper
• Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

  2017cites this paper
• Glomerular disease: Rituximab therapy for IgA nephropathy

  2017cites this paper
• Mycophenolate Mofetil therapy in IgA Nephropathy: Histological changes after treatment

  2017cites this paper
• Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease

  2016cites this paper
• Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.

  2016cites this paper
• Primary glomerulonephritides.

  2016cites this paper
• Open Peer Review

  2016cites this paper
• High Prevalence of Hyperuricemia and Gout inNorth American Patients with IgA Nephropathy

  2016cites this paper
• Hyperuricemia and Obesity in North American and European Children with IgA Nephropathy

  2016cites this paper